Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

September 16, 2022 0

Intellia Therapeutics Intellia Therapeutics.(NTLA) and Regeneron Pharmaceuticals (REGN) today announced positive interim results from an ongoing Phase 1 …

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

September 15, 2022 0

Rhythm Pharmaceuticals Rhythm Pharmaceuticals (RYTM): After soaring, based on great scientific and drug performance in treating …

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

September 13, 2022 0

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company, today released topline data from HARMONY, a …

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for ALS

September 8, 2022 0

Amylyx Pharmaceuticals in the News Amylyx Pharmaceuticals (AMLX): The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee has …

IVERIC Bio: Undeniable Promising News Today

September 6, 2022 0

IVERIC Bio ~ September 6, 2022 IVERIC bio (ISEE) announced positive results from GATHER2 second Phase …

TG Therapeutics: Promising Investigational Monoclonal Antibody Ublituximab for Relapsing Form of M.S.

August 31, 2022 0

TG Therapeutics Results Published in NEJM TG Therapeutics (TGTX) results from the ULTIMATE I & II …

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002 Aimed at Treating Hereditary Angioedema

August 30, 2022 0

Intellia Therapeutics to Present Interim Clinical Data from NTLA-2002 Trial for Hereditary Angioedema An abstract featuring interim …

Fate Therapeutics: Improving on Cellular Therapies

August 25, 2022 0

Fate Therapeutics: Developing Next Generation Cellular Therapies Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company developing first-in-class …

Important Data Will Be Presented by Regenxbio on August 30th

August 23, 2022 0

Regenxbio to Present Important Data Regenxbio (RGNX) will present important material at the Society for the …

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

August 15, 2022 0

Gilead Sciences Good News for Breast Cancer Gilead Sciences' (GILD) product Trodelvy® has significantly improved the Overall …

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals’ Product AMX0035 for ALS

August 11, 2022 0

On September 7th the FDA Will Review Amylyx Pharmaceuticals NDA for ALS Treatment Amylyx Pharmaceuticals (AMLX) …

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant Cancers

August 10, 2022 0

Hutchmed: Treating Advanced Refractory Metastatic Colorectal Cancer On August 8, 2022, Hutchmed (HCM) announced that pivotal global …

Reata Pharmaceuticals Announces Extension of Review Period for Omaveloxolone NDA for Friedreich’s Ataxia

August 9, 2022 0

Reata Pharmaceuticals in the NEWS Reata Pharmaceuticals (RETA) on August 8, 2022, after the U.S. financial …

Gilead Sciences: A Promising Acquisition. See Also: Genmab and BioNTech: A Promising Expansion

August 5, 2022 0

Gilead Sciences to Acquire MiroBio At $405 Million Gilead Sciences (GILD) and MiroBio - a privately …

Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

August 3, 2022 0

Regenxbio in the NEWS Regenxbio (RGNX) announced, on August 3, 2022, its intention to file a …

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn’s Disease

July 29, 2022 0

Offsetting the Biotech Firms' Good News There is no doubt that good news is filling the …

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

July 26, 2022 0

Seagen, Astellas Pharma & Merck Collaboration Seagen (SGEN) and Astellas Pharma (ALPMY) have entered a clinical …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for ALS

IVERIC Bio: Undeniable Promising News Today

TG Therapeutics: Promising Investigational Monoclonal Antibody Ublituximab for Relapsing Form of M.S.

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002 Aimed at Treating Hereditary Angioedema

Fate Therapeutics: Improving on Cellular Therapies

Important Data Will Be Presented by Regenxbio on August 30th

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals’ Product AMX0035 for ALS

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant Cancers

Reata Pharmaceuticals Announces Extension of Review Period for Omaveloxolone NDA for Friedreich’s Ataxia

Gilead Sciences: A Promising Acquisition. See Also: Genmab and BioNTech: A Promising Expansion

Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

Bristol-Myers Squibb Combination Improving the Treatment of Metastatic Melanoma; AbbVie Improving the Treatment of Crohn’s Disease

Seagen and Astellas Pharma Announced Positive Topline Results For PADCEV® with KEYTRUDA® as First-Line Treatment for Advanced Urothelial Cancer

Why Rhythm Pharmaceuticals Stock Price is Rebounding

Incyte Announces the FDA Approved its Opzelura Cream for the Treatment of Vitiligo

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene Therapy Vectors for Ocular Diseases